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Abstract
Synovial biopsy techniques have developed and widely expanded over the past few years, in particular due to the development of
ultrasound-guided procedures. This article reviews the different techniques, clinical applications, and the latest advances in
translational research as well as current challenges and perspectives. The first part focuses on different techniques available
for biopsy, along with their feasibility, success rate, tolerance, and training requirements. In the second part, clinical applications
are described. Data on diagnostic performances are reported, especially regarding septic arthritis. Translational research appli-
cations are described and explained in the final part, from the early histological studies and the first description of pathotype to
more recent technologies involving -omics. Latest developments involving single-cell RNA sequence analysis have allowed the
discovery of new cell subpopulations with remarkable roles in RA pathophysiology. These studies pave the ground for the
discovery of new therapeutic targets and the implementation of personalized therapy in RA.
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Different biopsy techniques
Brief history and introduction of techniques
Arthroscopic synovial biopsy has traditionally been considered the
gold standard for obtaining synovial tissue. It enables the operator
to view the synovium macroscopically and choose where to take
the biopsy [1]. Themacroscopic inspection can also yield diagnos-
tic information [2]. With the invention of thinner arthroscopes, the
procedure became less invasive, and more rheumatologists per-
formed arthroscopic biopsies throughout the 1990s [3].
However, arthroscopic synovial biopsies are invasive, ex-
pensive, and not widely available. Alongside the practice of
arthroscopic synovial biopsy procedures, less invasive, sim-
pler, and cheaper techniques for obtaining synovial biopsies
were developed. Early blind biopsy needles measured 5 mm
across so remained invasive [4]. Subsequent blind biopsy
needles, like the Parker and Pearson needle, were thinner
(14G, 15G, and 18G) and widely used [5, 6]. Samples obtain-
ed from the suprapatellar pouch by blind needle biopsies show
broadly similar features to samples taken using arthroscopy
[4, 7], but sufficient tissue for histological analysis is only
obtained in 61 to 85% of cases [8, 9]. The procedure is also
limited to larger joints.
To improve success rates and ensure that biopsies are taken
from the synovium, imaging-guided biopsy techniques
evolved. Imaging modalities reported include fluoroscopy
and CT scanning [10, 11], but ultrasound (US) has become
the preferred method to visualize the joint. US is free of ion-
izing radiation, and many rheumatologists use US in their
daily clinical practice.
Since first reported in 1997 [12], US-guided synovial biop-
sies (US-SB) are now routinely performed in many centres
throughout the world. An advantage of US-SB over
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arthroscopic and blind biopsies is that they can safely and
successfully be performed on both large and small joints
[13–15]. Themost frequently biopsied joints are wrists, knees,
MCPs, and ankles, but also elbows, shoulders, hips,
sternoclavicular, acromioclavicular, and pubic symphysis bi-
opsies are performed [13, 15, 16]. Figure 1 shows photos of an
US-SB being performed, and the microscopic appearances of
the tissue obtained.
What is involved for the patient?
Arthroscopic synovial biopsies are typically performed in an
operating theatre or in a procedure room [3]. Most are per-
formed using local anaesthetic, but general anaesthetic is used
in more than 1 in 5 procedures [16]. Half of the centres always
or often prescribe sedation [3]. Two ports are required: one for
the arthroscope and one for the biopsy forceps. The diameter
of the arthroscope is between 1.9 and 4.5 mm [6]. The oper-
ator can inspect the macroscopic appearance of the joint and
choose the biopsy site. Adequate samples can be obtained also
after inflammation has been successfully treated [6]. Joint la-
vage with saline can be performed, and this can be therapeutic
[1]. The port sites are usually closed with steristrips, though
sutures are sometimes used [3]. No specific observation is
required for most procedures.
US-SB require less specialist equipment than arthroscopic
biopsies. They can be obtained using portal and biopsy for-
ceps or a semi-automated core biopsy needle. In both cases,
local anaesthetic is infiltrated into the skin, soft tissues, and
synovial space. For portal and forceps, the portal is inserted
into the synovial space under US guidance and biopsy forceps
introduced through the portal. Semi-automated core biopsy
needles can either be introduced repeatedly through the same
tract under US guidance or through an introducer which acts
as a portal. US grey scale and power Doppler signal guide the
operator to the site of the highest inflammation. Multiple sy-
novial biopsies are taken, ideally from different parts of the
joint. As the puncture site usually is no larger than 2 mm, steri
strips are sufficient to close the wound. The procedure typi-
cally takes less than 1 h to perform, and patients can leave
soon thereafter. Patients are advised to rest the biopsied joint
for 48 h after the procedure.
Patient acceptance and tolerability
Minimally invasive synovial biopsy procedures are well-tol-
erated. A comparison of 402 US-guided needle biopsies, 65
US-guided portal and forceps biopsies, and 57 arthroscopic-
guided synovial biopsies did not identify any difference in the
post-biopsy pain, swelling, or stiffness between the three pro-
cedures [16]. Pain, swelling, and stiffness are unchanged or
a c
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Fig. 1 a and b Ultrasound guided
synovial biopsy. a Procedure with
the semi-automatic guillotine
needle. b US image of a shoulder
synovitis and the biopsy needle. c
and d Synovial tissue from an in-
flamed knee joint in RA. c
Haematoxylin and Eosin staining.
d CD68+ macrophages staining
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reduced following biopsy compared to before the procedure
[16–18]. Steroids reduce post-procedure swelling significant-
ly but do not improve pain or stiffness significantly [16]. The
discomfort during the procedure is higher for large joints than
small- and medium-sized joints [17].
The majority of patients is somewhat or very likely to agree
to another biopsy, with patient undergoing US-guided needle
biopsies less willing than those undergoing US-guided portal
and forceps biopsies or arthroscopic biopsies [16–18]. The
willingness does not decline after a second biopsy [16].
Complications
The complication rates of minimally invasive arthroscopic and
US-SB are similar between studies and summarized in Table 1.
Based on a survey of 15682 procedures, the most common
complications of arthroscopic synovial biopsies performed by
rheumatologists are haemarthosis in 0.9% and DVT in 0.2%
of patients. Joint infection, wound infection, and neurological
damage occur in 0.1%, 0.1%, and 0.02%, respectively [3].
Studies on the complication rates of US-SB are smaller,
and many do not report any major complications. The largest
study to date included 402 US-guided needle biopsies and 65
US-guided portal and forceps biopsies and identified a com-
plication rate of 8/467 (1.71%) [16]. These comprised of 2
episodes of syncope or presyncope, 1 tenosynovitis, 4 sensory
impairment, and 1 haemarthrosis. Syncope or presyncope
have been reported by others as between 0.8 and 3.2% [16,
17, 19]. Motor neurological complications, both transient pa-
resis due to local anaesthesia and persistent mild limitation of
digit extension, have occurred following wrist biopsies [18].
Minor bleeding occurs in up to 7.8% of procedures [18], but
haemarthrosis is rare with rates up to 1.3% in individual stud-
ies [15]. Skin infection was reported in one study [14].
The most common minor complications following US-SB
are mild arthralgia and increased use of analgesia following
the procedure, occurring following 19.4% and 36% proce-
dures, respectively [17, 18]. There is no increase in adverse
event in patients on biologic treatments [17].
Success of procedure
The definition of success varies between studies historically.
Current recommendations stipulate that the synovial lining
layer should be present and that an area of 2.5 mm2 is required
for representative staining [22]. Due to tissue heterogeneity, it
is recommended that at least four biopsies are taken from
small joints and six biopsies from large joints [22]. The yield
of tissue depends on US grey scale synovitis with the highest
yield with synovial grade 3 [17]. There is a trend for more
successful samples from large joints than small joints.
Of 7 studies included in a systematic review, only three clear-
ly defined success as an intact lining layer [13]. The success rate
in these three studies was 89–100%. A somewhat lower success
rate of US-SB was reported in an observational study in which
62 of 76 clinical procedures (81.6%) yielded synovial tissues
[15]. Synovial lining was seen in 92.6% of successful proce-
dures. The failed biopsies occurred in both small and large joints,
and the authors comment that inexperience contributed to biopsy
failure. The proportion of gradable synovial tissue is lower when
blind needle biopsies are used compared to US-guided and ar-
throscopic procedures [9]. For large joints, US-SB perform as
well as arthroscopic biopsies.
Training
Arthoscopic biopsies require considerable training.
Observation of 5 procedures, assisting at 10 procedures and
performing 10 procedures supervised, has been proposed as
adequate training before independence [3]. More recently, the
European League Against Rheumatism (EULAR) has been
working towards the creation of a EULAR standardized
Table 1 Success rate, complications, and tolerability of arthroscopic and US-guided synovial biopsies [1, 3, 13–21]
Arthroscopic US-guided biopsy semi-automatic needle US-guided biopsy portal
and forceps
Success rate > 90% Around 80–90% depends on
US grey scale
synovitis grade, joint size, and
operator experience
Around 80–90%
Complications 1.51% complication rate, haemarthrosis 0.9%,
DVT 0.2%, wound infection 0.1%, joint
infection 16 0.1%, thrombophlebitis 0.08%,
flare of gout 0.06%, syncope/vasovagal 0.02%,
neurological 0.02%
Minor bleeding up to 7.8%,
haemarthrosis 0.3–1.3%,
neurological up to 3.1%, vasovagal
symptoms 0.8
to 3.2%, rare: tenosynovitis
Skin infection (1 of 37
procedures in one study)
Tolerability 62% no or mild discomfort 70–92.8% no or mild discomfort 71% no or mild discomfort
Willingness of repeat
biopsy
64% likely or somewhat likely 57–74% likely or somewhat likely 85% likely or somewhat
likely
Fewer studies have reported on US-guided port-and-forceps biopsies than arthroscopic and US-guided needle biopsies
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training model for ultrasound-guided synovial biopsy proce-
dures in large and small joints leading to an educational video
and recommendations (Moller et al., ongoing).
Clinical utility
Synovial biopsy to exclude infection
The most common clinical indication for synovial biopsies is to
rule out septic arthritis [15, 20]. In a study reporting on 76 US-
guided procedures performed with clinical indications, 82.4%
was performed to rule out septic arthritis [15].Most patients had
an undifferentiated chronic monoarthritis (54.1%) or an acute
monoarthritis (24%), but cases of chronic undifferentiated
oligoarthritis, chronic polyarthritis, chronic bursitis, chronic te-
nosynovitis, and acute polyarthritis were also biopsied. Two
cases of infectious arthritis were identified, namely Lyme’s
disease and articular Whipple disease [15]. In the case of
Whipple disease, the synovial fluid PCR had been negative.
No other case of infectious arthritis was identified during fol-
low-up, suggesting that synovial biopsy is reliable in excluding
septic arthritis. The reliability of synovial biopsies to exclude
infection in native joints has been replicated by others [18, 19].
A causative organism is identified in less than half of pa-
tients who clinically have septic arthritis, and a synovial biopsy
can be informative [20, 23]. In a study where 90% of partici-
pants had a synovial fluid aspirate and 25% had a synovial
biopsy taken, the causative organism was grown in 38.7% of
synovial fluid samples and 23.5% of synovial membranes.
Antibiotics had not been given prior to synovial fluid aspirate
but could have been given before the synovial biopsy.
Nonetheless, in three cases (one mycobacterium and two
Staphylococcus aureus), the synovial tissue was positive on
culture, but the synovial fluid was negative [20, 23].
Moreover, bacterial DNA is detectable in synovial tissue for
longer than gram stain and positive cultures and can be detect-
ed after empirical antibiotics have been started [24]. A high
synovial neutrophil (CD15+) count (absolute and relative) is
also supportive of a diagnosis of septic arthritis [20, 25]. When
synovial biopsies are performed in patients with suspected in-
fectious arthritis, qPCR analysis for 16S RNA, Borrelia
Burgdorferi and TropherymaWhipplei are recommended [22].
Diagnoses made with synovial biopsies
In most cases, synovial biopsies taken with clinical indications
do not yield a specific diagnosis [15, 18]. Nonetheless, a number
of specific diagnosis have been reported, including gout and
pseudogout with deposits found within the synovial tissue, even
when synovial fluid analysis is negative [6, 15, 18]. Importantly,
the synovial tissue needs to be preserved in absolute ethanol
rather than formalin to prevent urate crystals from dissolving.
Other pathologies which can be identified on synovial bi-
opsy include amyloidosis with deposits which stain red with
Congo red stain and synovial chondromatosis with cartilage
nodules seen within the synovial tissue [18, 26]. In
ochronosis, haemachromatosis, and recurrent haemarthrosis,
specific pigments are seen. A brown colour frommacrophages
carrying haemosiderin is also seen in pigmented villonodular
synovitis along with hypercellularity in the sublining layer.
There are rare synovial malignancies including synovial
chondrosarcoma, synovial haemangiomas, lipoma
aborescens, and intracapsular chondromas [26]. The patholog-
ical diagnosis of tumours identified by synovial biopsies is
compatible with pathological diagnosis from synovectomy
samples [19]. Also lymphoprolipherative disorders can pres-
ent within the synovium, and sarcoidosis, foreign body arthri-
tis, the histiocytic disorder Erdheim-Chester disease and
multicentric reticulohistocytosis have been diagnosed with
synovial biopsies [15, 18, 19, 27].
Utility in inflammatory arthritis
In cases lacking clear distinguishing pathological features,
synovial biopsies can still support a diagnosis of inflammatory
arthritis. The Krenn score gives a score between 0 and 3 to the
histological features of enlargement of synovial lining cell
layer, density of resident cells, and inflammatory infiltrate. It
defines synovitis histologically as low-grade (2–4) and high-
grade (5–9) synovitis [28]. Using the cut-off of 4, inflamma-
tory arthritis can be differentiated from healthy controls and
degenerative disease with a specificity of 96.1% and sensitiv-
ity of 61.7% [28]. By adding immunostaining with CD68,
CD3, CD20, CD31, and Ki67, the specificity and sensitivity
for differentiating inflammatory arthritis from osteoarthritis
are improved [29].
To date, there is no validated histological score which can
differentiate between different types of inflammatory arthritis
in individual patients. On a disease level, however, there are
differences. Patients with spondyloarthritis (SpA) have in-
creased vasculature with tortuous vessels, and this is seen both
macroscopically and microscopically [1, 30]. The cellular in-
filtrate in the synovium is different depending on the presence
of a joint effusion in RA and SpA [30]. Patients with RA with
joint effusions have increased B cell and T cell staining com-
pared to patients with SpA with joint effusions. Furthermore,
patients with early RA have increased staining of plasma cells,
B cells, and macrophages compared to non-RA early arthritis
[31]. Minimal staining of plasma cells and macrophages pre-
dicts a diagnosis other than RA in 96% cases [31]. In addition,
specific synovial signatures including the expression of
chemokines ((C-X-C motif) ligand 4 (CXCL4) and
CXCL7), and fibroblast activation protein (FAP) differentiate




With the wider availability of US-SB, the procedure is increas-
ingly used to obtain tissue for research. Thus, the analysis of
synovial tissue has been used over the past few decades in trans-
lational research to increase our knowledge and understanding of
the pathophysiology of rheumatic diseases, to predict treatment
response, and to help discover new therapeutic targets.
Given the sensitivity to change of the tissue, especially in
terms of cell infiltrate, synovitis histological assessment is
considered a reliable biomarker of response to treatment [34].
Histological stratification
Histological analysis, by permitting the analysis of tissue cell
infiltrates in RA synovium, allows for better stratification of
RA patients across disease states and phenotypes. This has led
to the concept of synovial pathotypes which was first intro-
duced by Dennis et al. [35]. Pathotypes are defined by a spe-
cific cell type enrichment within the synovial tissue and are
associated with a well-defined underlying molecular signature
[35]. Four different pathotypes were initially described: lym-
phoid enriched in B and T cells, myeloid enriched in macro-
phages, fibroid, and pauci-immune [35]. The concept of
pathotypes was further developed by others as lympho-mye-
loid, diffuse-myeloid, and pauci-immune, and these three pat-
terns are present also in early RA [21, 36].
Numerous studies have assessed the relationship between
pathotypes and RA disease phenotypes. The lymphoid
pathotype is associated with the presence of ectopic lymphoid
follicles. Their presence in the synovial tissue has been incon-
sistently reported as associated with disease activity and an
erosive RA phenotype [21, 37–40]. The pauci-immune phe-
notype is associated with lower levels of CRP [21, 41].
This being said, cell populations within the synovial mem-
brane infiltrate are highly heterogeneous, and are influenced by
many different parameters, such as disease duration [42], ACPA
status in RA [43, 44], disease activity [45], and biological treat-
ment. Therefore, studies focusing on gene expression signatures
in addition to, or instead of, the histological cell composition
have been developed in order to provide a more accurate patient
stratification and personalized therapies approaches.
Towards personalized therapy using molecular
signatures
The histological pathotypes are associated with well-defined
molecular signatures [21, 35, 46]. The inclusion of this infor-
mation in prediction models can improve the sensitivity and
specificity of patients’ classification in comparison to 1987
ACR criteria [47] in a cohort of 200 early arthritis patients,
including RA and undifferentiated arthritis patients [46].
Myeloid- and lymphoid-associated genes correlate to disease
activity and response to treatment at 6 months, while a lym-
phoid molecular signature correlates to an osteoclasts-related
gene enrichment and predicted structural damages progression
at 12 months [21].
Although histologically defined pathotypes are not associated
with csDMARD response in early RA, related molecular signa-
tures are associated with response to csDMARDs [21].
Furthermore, the lympho-myeloid pathotype, with enriched in-
flammatory gene expression including IL-6 and TNFα, is asso-
ciated with a higher prescription of biological DMARDs [46].
Pathotypes and molecular signatures have also been used to
predict response to biological treatments. For example, patients
with the myeloid phenotype are better responders to TNF block-
ade [35], and transcripts associated with lymphoid pathotype
predict a good response to infliximab therapy [48]. Enrichment
of B cells in cellular infiltrates and B cell linage transcripts on the
other hand are associated with a poor response to TNF inhibitors
[49], as is the pauci-immune phenotype [41].
Of interest, Badot et al. performed gene expression studies
along with immunohistochemistry without consideration of
pathotypes [50]. They demonstrated that high baseline syno-
vial expression of interleukin-7 receptor alpha chain (IL-7R),
CXCL11, IL-18, IL-18 receptor accessory (IL-18rap), and
MKI67 predicts a poor response to adalimumab therapy [50].
These studies show promise for personalized medicine in
RA, and further studies are ongoing. Alongside, new single-
cell and -omics technologies are rapidly improving our under-
standing of disease pathophysiology and may enable the iden-
tification of new therapeutic targets.
New single-cell technologies
New distinct cell subpopulations have been identified in RA
using technologies linking transcriptomics and proteomics
through single-cell RNA seq, mass spectrometry, bulk RNA
seq, and flow cytometry. The Accelerating Medicines
Partnership Rheumatoid Arthritis and Lupus (AMP RA/
SLE) consortium mapped cell subpopulations according to
their production of cytokines [51]. Indeed, new T cell popu-
lations, such as PDCD1+ T peripheral helper and T follicular
helper T cells, were newly described, and a pro-inflammatory
subpopulation of sublining fibroblasts, THY1(CD90)+HLA-
DRAhi, is the main producer of IL-6. The pathogenic role of
resident synovial fibroblasts was also emphasized in recent
work from Croft et al., who described novel fibroblast sub-
populations within RA synovial tissue using single-cell RNA
sequencing [52]. Two populations with distinct roles were
described: the fibroblast activation protein-α (FAPα)- posi-
tive thymus cell antigen 1 (THY1) positive synovial fibro-
blasts (FAPα+THY1+) located in the synovial sublining and
able to regulate inflammation through cytokines and
chemokines secretion, and the FAPα+THY1-fibroblasts
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located in the lining layer responsible for bone and cartilage
destruction and an invasive phenotype.
More recently, Alivernini et al. studied macrophage sub-
populations across disease states in RA, using synovial tissue
from active RA and remission [53]. They identified two new
subpopula t ions of synovia l t i s sue macrophages
(MerTKposCD206pos and MerTKposLYVE1pos) displaying
transcriptomic signatures enriched in negative regulators of
inflammation. The presence of these populations was associ-
ated with remission maintenance, suggesting a promising po-
tential therapeutic role of these cells in RA.
Although most work has focused on RA, Wade et al. identi-
fied a polyfunctional T cell subset in PsA using flow cytometry
of digested PsA synovial tissue [54]. These CD4 + CD161+ T
cells produce high concentrations of pro-inflammatory cytokines,
including IL-17A, IFNγ, and TNF. Their presence correlates
highly to PsA disease activity expressed by the disease activity
in psoriatic arthritis (DAPSA).
Further agenda in the field of synovial tissue research in-
cludes projects related to education, clinical applications,
translational research, quality appraisal of research, and ther-
apy. The research agenda is detailed in Table 2.
In conclusion, RA and other rheumatic diseases are char-
acterized by synovial inflammation, and the retrieval and anal-
ysis of synovial biopsies have improved the understanding of
disease pathophysiology. Minimally invasive US-SB tech-
niques are safe, well-tolerated, and widely performed. In ad-
dition to a demonstrated utility in different clinical situations,
synovial tissue analysis, at a cellular and molecular level ini-
tially and a molecular lever more recently, has driven impor-
tant developments in rheumatology. The implementation and
use of cutting-edge technologies in translational research are
currently allowing new insights and identification of new cell
subsets involved in different states of rheumatic diseases.
Such data will allow a better understanding of disease pheno-
types, predict treatment response, and constitute a rationale for
the development of new cell-targeted therapies.
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